AI assistant
ACADIA PHARMACEUTICALS INC — Director's Dealing 2021
Apr 30, 2021
31237_dirs_2021-04-30_2cfc29b8-9bde-4944-ba9e-97abd906775d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2021-04-29
Reporting Person: KIM AUSTIN D. (EVP & General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-04-29 | Common Stock | M | 3005 | — | Acquired | 12425 | Direct |
| 2021-04-30 | Common Stock | S | 1054 | $20.33 | Disposed | 11371 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-04-29 | Restricted Stock Units | $ | M | 3005 | Disposed | Common Stock (3005) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
F2: The amount of securities beneficially owned reported in Column 5 above has been adjusted to correct an error in the Reporting Person's prior Form 4 caused by the failure to carry over the correct number of shares from the prior report. The number of shares owned prior to the transactions reported herein was 9,420 shares.
F3: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4: The restricted stock units vest in four equal annual installments beginning 4/29/2020.